<DOC>
	<DOCNO>NCT02727933</DOCNO>
	<brief_summary>The primary objective study describe safety combination Daklinza ( daclatasvir ) Sunvepra ( asunaprevir ) use treatment chronic hepatitis C ( CHC ) genotype 1b patient real-life condition use accord registered indication .</brief_summary>
	<brief_title>Postmarketing Surveillance Safety Effectiveness Daclatasvir Asunaprevir Treatment Chronic HCV Genotype 1B Infection Routine Clinical Practice Korea</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Patients CHC genotype 1b compensate liver disease , include cirrhotic patient Eligible treatment Daklinza Sunvepra indicate locally approve prescribing information . Offlabel use Daklinza Sunvepra Patients contraindication use Daklinza Sunvepra describe locally approve prescribing information</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>